Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

Matko Kalac; Jennifer K. Lue; Emily Lichtenstein; Ithamar Turenne; Celeste Rojas; Jennifer E. Amengual; Ahmed Sawas; Changchun Deng; Markus Y. Mapara; Joseph M. Connors; John Kuruvilla; Owen A. O'Connor

doi:10.1111/bjh.14449

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

Matko Kalac, Jennifer K. Lue, Emily Lichtenstein, Ithamar Turenne, Celeste Rojas, Jennifer E. Amengual, Ahmed Sawas, Changchun Deng, Markus Y. Mapara, Joseph M. Connors, John Kuruvilla, Owen A. O'Connor

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	757-760
Number of pages	4
Journal	British Journal of Haematology
Volume	180
Issue number	5
DOIs	https://doi.org/10.1111/bjh.14449
State	Published - Mar 2018
Externally published	Yes

Keywords

Hodgkin lymphoma
antibody-drug conjugate
autologous stem cell transplant
monoclonal antibodies
refractory disease

Access to Document

10.1111/bjh.14449

Cite this

Kalac, M., Lue, J. K., Lichtenstein, E., Turenne, I., Rojas, C., Amengual, J. E., Sawas, A., Deng, C., Mapara, M. Y., Connors, J. M., Kuruvilla, J., & O'Connor, O. A. (2018). Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. British Journal of Haematology, 180(5), 757-760. https://doi.org/10.1111/bjh.14449

@article{e9fe4e8cbe0242b390f15a6a1ed207aa,

title = "Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma",

keywords = "Hodgkin lymphoma, antibody-drug conjugate, autologous stem cell transplant, monoclonal antibodies, refractory disease",

author = "Matko Kalac and Lue, {Jennifer K.} and Emily Lichtenstein and Ithamar Turenne and Celeste Rojas and Amengual, {Jennifer E.} and Ahmed Sawas and Changchun Deng and Mapara, {Markus Y.} and Connors, {Joseph M.} and John Kuruvilla and O'Connor, {Owen A.}",

year = "2018",

month = mar,

doi = "10.1111/bjh.14449",

language = "English",

volume = "180",

pages = "757--760",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Kalac, M, Lue, JK, Lichtenstein, E, Turenne, I, Rojas, C, Amengual, JE, Sawas, A, Deng, C, Mapara, MY, Connors, JM, Kuruvilla, J & O'Connor, OA 2018, 'Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma', British Journal of Haematology, vol. 180, no. 5, pp. 757-760. https://doi.org/10.1111/bjh.14449

TY - JOUR

T1 - Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

AU - Kalac, Matko

AU - Lue, Jennifer K.

AU - Lichtenstein, Emily

AU - Turenne, Ithamar

AU - Rojas, Celeste

AU - Amengual, Jennifer E.

AU - Sawas, Ahmed

AU - Deng, Changchun

AU - Mapara, Markus Y.

AU - Connors, Joseph M.

AU - Kuruvilla, John

AU - O'Connor, Owen A.

PY - 2018/3

Y1 - 2018/3

KW - Hodgkin lymphoma

KW - antibody-drug conjugate

KW - autologous stem cell transplant

KW - monoclonal antibodies

KW - refractory disease

UR - http://www.scopus.com/inward/record.url?scp=85032451762&partnerID=8YFLogxK

U2 - 10.1111/bjh.14449

DO - 10.1111/bjh.14449

M3 - Letter

C2 - 27984643

AN - SCOPUS:85032451762

SN - 0007-1048

VL - 180

SP - 757

EP - 760

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -